Filing Details
- Accession Number:
- 0001689375-22-000046
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-18 16:59:53
- Reporting Period:
- 2022-11-16
- Accepted Time:
- 2022-11-18 16:59:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1689375 | Entrada Therapeutics Inc. | TRDA | Pharmaceutical Preparations (2834) | 813983399 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1725663 | James Kory Wentworth | C/O Entrada Therapeutics, Inc. 6 Tide Street Boston MA 02210 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-11-16 | 200 | $2.10 | 16,709 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-11-16 | 200 | $18.10 | 16,509 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-11-16 | 200 | $0.00 | 200 | $2.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
108,607 | 2030-11-10 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
- The Form 4 filed by the reporting person on August 18, 2022 inadvertently understated the number of common shares owned following the transactions reported therein by 20 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Immediately prior to the transactions reported herein, the correct number of shares of common stock owned by the reporting person was 16,509 shares.
- 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.